Seminars in Cancer Biology

Article	Citations
Editorial Board	671
Expression of concern “Decoding T cell senescence in cancer: Is revisiting required?” [Semin. Cancer Biol. 108 (2025) 33–47]	472
Small secretory proteins of immune cells can modulate gynecological cancers	426
Advances in biology and novel treatments of SCLC	390
Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications	386
Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation	332
Multifaceted role of chemokines in solid tumors: From biology to therapy	290
Microbiome-modulated immunotherapy in oncology: Current applications and future prospects	260
Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation	255
Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator	246
Emerging applications of bacteria as antitumor agents	239
Critical DNA damaging pathways in tumorigenesis	238
Deregulated transcription factors in the emerging cancer hallmarks	236
Editorial Board	228
Special issue: Deregulated transcription factors in the cancer therapeutic challenges: An update on cancer stemness features	226
Association of Chlamydia and Mycoplasma infections with susceptibility to ovarian cancer: A systematic review and meta-analysis	215
Gut microbes in gastrointestinal cancers	210
Erratum to “RNA regulatory mechanisms controlling TGF-β signaling and EMT in cancer” [Semin. Cancer Biol. 102–103 (2024) 4–16]	193
Expression of concern: “Combined targeting of senescent cells and senescent macrophages: A new idea for integrated treatment of lung cancer” [Semin. Cancer Biol. 106–107 (2024) 43–57]	192
Immune cellular components and signaling pathways in the tumor microenvironment	191
Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in pancreatic cancer	187
Excess body weight and postmenopausal breast cancer: Emerging molecular mechanisms and perspectives	183
Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy	170
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy	166
Origins and molecular effects of hypoxia in cancer	164

Innovative trial design in precision oncology	163
The IL-1 family in tumorigenesis and antitumor immunity	162
The impact of obesity and lipids on cancer: Insights into mechanisms and potential interventions	162
Cracking the resistance code: The molecular reclassification of cancer and precision therapy strategies	161
Anticancer properties of chimeric HDAC and kinase inhibitors	159
Extracellular vesicles associated microRNAs: Their biology and clinical significance as biomarkers in gastrointestinal cancers	159
The emerging role of metabolic interventions in uveal melanoma	158
Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics?	155
Enhancing head and neck tumor management with artificial intelligence: Integration and perspectives	152
Atrial fibrillation in cancer patients: Epidemiology, identification and management	145
The role of deiodinases on metabolic alteration in cancer	141
Systemic lipid metabolic alterations and the tumor microenvironment: A hidden driver of immune dysfunction	139
Editorial Board	130
Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools	130
Metabolic landscape and rewiring in normal hematopoiesis, leukemia and aging	129
Therapy-induced modulation of extracellular vesicles in hepatocellular carcinoma	129
Integrating biomarkers, experimental models, genomics, and novel therapeutics for pancreatic cancer precision medicine	129
Expression of concern “Immunosenescence in digestive system cancers: Mechanisms, research advances, and therapeutic strategies” [Semin. Cancer Biol. 106–107 (2024) 234–250]	127
Reprogramming of glycolysis by chemical carcinogens during tumor development	126
Editorial Board	126
Regulation of the aryl hydrocarbon receptor in cancer and cancer stem cells of gynecological malignancies: An update on signaling pathways	122
Insight into the role of multiple signaling pathways in regulating cancer stem cells of gynecologic cancers	120
Vibrational spectroscopy for decoding cancer microbiota interactions: Current evidence and future perspective	118
Anticancer natural products targeting immune checkpoint protein network	117
Lipid metabolism in cancer is regulated by the integrated natural product–miRNA–target axis	112
Targeting the “undruggable”: RNA-binding proteins in the spotlight in cancer therapy	108
Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems	106
Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics	105
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine	103
Multi-omic markers of intraductal papillary mucinous neoplasms progression into pancreatic cancer	102
Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics	101
Editorial Board	98
How far have we explored fungi to fight cancer?	98
Editorial Board	98
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer	98
Role of ubiquitination-driven metabolisms in oncogenesis and cancer therapy	92
Cytotoxic activity of l-lysine alpha-oxidase against leukemia cells	92
Mechanisms and applications of apolipoproteins and apolipoprotein mimetic peptides: Common pathways in cardiovascular disease and cancer	92
Mitochondria in sarcoma and carcinoma: Achilles’ heel or Hercules’ strength?	92
Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment	92
Editorial Board	92
Transcription networks rewire gene repertoire to coordinate cellular reprograming in prostate cancer	91
Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer	91
Chaperonins in cancer: Expression, function, and migration in extracellular vesicles	91
Drivers of centrosome abnormalities: Senescence progression and tumor immune escape	89
Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders	88
Cancer therapy-related cardiovascular toxicity: Current progress and future perspectives	88
Microbiota and lung cancer	87
Clinical utility of whole-genome sequencing in precision oncology	83
Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling	83

The microbiome-immune cell interaction network: Advancing tumor immunotherapy	83
Microorganisms in cancer tertiary lymphoid structure formation	82
Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications	81
BubR1 and SIRT2: Insights into aneuploidy, aging, and cancer	81
Analytical demands to use whole-genome sequencing in precision oncology	81
Functionalized-DNA nanostructures as potential targeted drug delivery systems for cancer therapy	80
Advancements in small cell lung cancer	80
Metabolic reprogramming of tumor microenviroment by engineered bacteria	80
Editorial Board	79
Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme	78
Beyond cardiovascular health: The pharmacotherapeutic potential of statins in oncology	77
Holistic immunomodulation for small cell lung cancer	77
Urinary microbiota and bladder cancer: A systematic review and a focus on uropathogens	77
Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications	76
Microbes in gynecologic cancers: Causes or consequences and therapeutic potential	76
Special issue: Lipid metabolic alterations in cancer: Pathogenic mechanisms, therapies and common pathophysiology with cardiovascular disease	76
Sanitation enzymes: Exquisite surveillance of the noncanonical nucleotide pool to safeguard the genetic blueprint	75
CRISPR/Cas mediated epigenome editing for cancer therapy	74
Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer	74
Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment	74
Anticancer activity of lactic acid bacteria	73
Editorial Board	73
Excess body weight: Novel insights into its roles in obesity comorbidities	73
Editorial Board	72
Thematic issue ‘tumor glycolysis’	71
Exosome-based nanomedicine for cancer treatment by targeting inflammatory pathways: Current status and future perspectives	71
Characterizing and exploiting the many roles of aberrant H2B monoubiquitination in cancer pathogenesis	71
Editorial Board	71
The intricate role of adipokines in cancer-related signaling and the tumor microenvironment: Insights for future research	70
Non-coding genome in small cell lung cancer between theoretical view and clinical applications	70
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges	70
Accelerating antibody discovery and design with artificial intelligence: Recent advances and prospects	69
Beyond cell cycle regulation: The pleiotropic function of CDK4 in cancer	69
Microbial metabolites for cancer immunotherapy: Current evidence and future directions	69
The impact of VEGF on cancer metastasis and systemic disease	68
Special Issue: Epigenetic regulation of cancer progression: Promises and progress	67
Deregulated transcription factors and poor clinical outcomes in cancer patients	67
TGF-β, EMT, and resistance to anti-cancer treatment	66
The role of RNA-binding proteins in the processing of mRNAs produced by carcinogenic papillomaviruses	65
Transcriptional factors targeting in cancer stem cells for tumor modulation	65
Editorial Board	65
Remodeling of tumor microenvironment by cellular senescence and immunosenescence in cervical cancer	64
Gut microbiota and immunosenescence in cancer	64
The intricate nature of senescence in development and cell plasticity	64
Obesity and main urologic cancers: Current systematic evidence, novel biological mechanisms, perspectives and challenges	63
Emerging role of pancreatic stellate cell-derived extracellular vesicles in pancreatic cancer	63
Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspective	62
Precision diagnostics in lymphomas – Recent developments and future directions	62
Microbiome unlocks cancer immunotherapeutic potential: State of the art and future	61
Obesity, type 2 diabetes and cancers of the digestive system	61
Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance	61
Inflammation-targeted nanomedicine against brain cancer: From design strategies to future developments	60
Microbes in lung cancer initiation, treatment, and outcome: Boon or bane?	60
Extracellular vesicles as source for the identification of minimally invasive molecular signatures in glioblastoma	60
Mechanisms and strategies of immunosenescence effects on non-small cell lung cancer (NSCLC) treatment: A comprehensive analysis and future directions	60
Alternative splicing in EMT and TGF-β signaling during cancer progression	59
Cathepsins: Emerging targets in the tumor ecosystem to overcome cancers	59
The Warburg effect: The hacked mitochondrial-nuclear communication in cancer	58
cGAS/STING signalling pathway in senescence and oncogenesis	58
Inflammation targeted nanomedicines: Patents and applications in cancer therapy	57
Artificial intelligence aids in development of nanomedicines for cancer management	57
Editorial Board	57
Nanoparticles: Attractive tools to treat colorectal cancer	55
Editorial Board	55
Vitamin D: What role in obesity-related cancer?	55
Editorial Board	55
Precision medicine in pediatric solid cancers	54
Corrigendum to “How far have we explored fungi to fight cancer?” [86/Part 2 (2022) 976–989]	54
Targeting oncogenic transcription factors in skin malignancies: An update on cancer stemness and therapeutic outcomes	54
Pro-tumoral functions of tumor-associated macrophage EV-miRNA	54
Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways	53
Epigenetic deregulation in cancer: Enzyme players and non-coding RNAs	53
Impaired cholesterol and LDL uptake pathways in the development of oncological and cardiovascular diseases	53
Dysregulated FOXM1 signaling in the regulation of cancer stem cells	52
The altered lipidome of hepatocellular carcinoma	52
The role of exercise in obesity-related cancers: Current evidence and biological mechanisms	52
“Time” for obesity-related cancer: The role of the circadian rhythm in cancer pathogenesis and treatment	51
New insights into KLFs and SOXs in cancer pathogenesis, stemness, and therapy	51
A role for partial epithelial-to-mesenchymal transition in enabling stemness in homeostasis and cancer	51
Hedgehog signaling mechanism and role in cancer	50

Small cell lung cancer: Novel treatments beyond immunotherapy	50
Interplay of ferroptosis, cuproptosis, and PANoptosis in cancer treatment-induced cardiotoxicity: Mechanisms and therapeutic implications	50
Exploiting transcription factors to target EMT and cancer stem cells for tumor modulation and therapy	50